Amicus Therapeutics — Q3 2020 Earnings Presentation
25 slides from Amicus Therapeutics's earnings presentation, Nov 5, 2020
Slide 1: 3Q20 Financial Results Conference Call & Webcast
3Q20 Financial Results Conference Call & Webcast November 5, 2020
Slide 2: Forward-Looking Statements
2 Forward - Looking Statements Introduction This presentation contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from precli
Slide 3: A leading fully integrated, global rare disease biotechnology company
3 A leading fully integrated, global rare disease biotechnology company Introduction Gene Therapy PLATFORM Protein Engineering & Glycobiology $509.1M Cash as of 9 /30/20 Two Clinical - Stage Gene Therapies AT - GAA Phase 3 in Pompe Disease GLOBAL COMMERCIAL ORGANIZATION World Class BIOLOGICS Capabil
Slide 4: 2020 Key Strategic Priorities
4 2020 Key Strategic Priorities Introduction 1 2 3 4 5 Achieve global product revenue for Galafold of $250M - $260M Complete Pompe Phase 3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA Advance clinical development, manufacturing and regulatory discussio
Slide 5: Galafold Global Launch
Galafold ® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 6: Galafold Snapshot (as of September 30, 2020)
6 Galafold Snapshot (as of September 30, 2020) Galafold: Precision Medicine for Fabry Disease One of the Most Successful Rare Disease Launches 348 Amenable Variants in U.S. Label 40+ Countries with Regulatory Approvals: including U.S., EU, Japan, and other Countries Continued Expansion in 2020 $ 67.
Slide 7: Galafold Quarterly Performance
7 $48.8M $ 67.4 M 3Q19 Operational Growth FX Impact 3Q20 Year - over - Year Sales Growth Galafold Quarterly Performance Growth remains steady with Q3 revenue of $67.4M; $65.7M on a constant currency basis Galafold: Precision Medicine for Fabry Disease 3Q19 vs 3Q20 +81% $ 48.8 M $ 55.3 M $ 60.5 M $ 6
Slide 8: Galafold Growth Trajectory
8 Galafold Growth Trajectory Galafold: Precision Medicine for Fabry Disease FY18 FY19 FY20 FY21 FY22 FY23 $91M $182M $500M+ ~$1B Projected Cumulative Revenues (2020 - 2022) $1B Annual Revenue Galafold is on track to generate $1B+ in projected cumulative revenues from 2020 - 2022 and is on an anticip
Slide 9: AT-GAA: Next Potential Standard of Care for Pompe Disease
AT - GAA: Next Potential Standard of Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement
Slide 10: AT-GAA: Foundation in Protein Engineering
10 AT - GAA: Foundation in Protein Engineering AT - GAA for Pompe Disease Amicus scientists created a uniquely glycosylated and highly phosphorylated ERT (AT - GAA) that significantly enhances targeting to key muscles affected
Slide 11: Amicus POM-002 Natural History Study
11 Amicus POM - 002 Natural History Study Data from the Amicus POM - 002 chart review study in patients treated long - term with alglucosidase alfa is consistent with the medical literature and further supports PROPEL design assumptions Note: The blue solid curve is the estimated trendline obtained
Slide 12: AT-GAA: Key Takeaways
12 AT - GAA: Key Takeaways AT - GAA for Pompe Disease AT - GAA for Pompe Advances Toward Approval as “Crown Jewel” of Amicus Portfolio • PROPEL study timelines are on track with data expected 1Q2021 – To date, 97%+ of the 3,100+ planned infusions and assessments for the ongoing PROPEL study have bee
Slide 13: Next Generation Gene Therapy Platform
“We have a duty to obsolete our own technologies” - Amicus Belief Statement Next Generation Gene Therapy Platform
Slide 14: Pipeline
14 DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold ® (migalastat) Monotherapy Fabry Gene Therapy PENN Pompe Franchise AT - GAA ( Novel ERT + Chaperone) Pompe Gene Therapy PENN Batten Franchise – Gene Therapies CLN6 Batten Disease NCH CLN3 Batten Disease NCH CLN
Slide 15: Interim Clinical Data for CLN6 Batten Disease Gene Therapy
15 Interim Clinical Data for CLN6 Batten Disease Gene Therapy The Hamburg Motor & Language (HML) Score, an assessment of ambulation and speech, shows a meaningful effect in slowing disease progression at 24 months Next Generation Gene Therapy Platform Proportion of Patients with a Change in the HML
Slide 16: Next Generation Gene Therapy Platform
16 Next Generation Gene Therapy Platform Team of 200+ scientists bringing expertise and experience in: Protein Engineering & Glycobiology Expertise Clinical and Regulatory Expertise Global Commercial Infrastructure Vectors, Tropisms, Capsids Safety Dosing, Immunology Manufacturing, Scalability Combi
Slide 17: Fabry Gene Therapy IND Candidate
17 Fabry Gene Therapy IND Candidate AAV with engineered GLA transgene demonstrated significantly better GL - 3 reduction than AAV with wild - type GLA. Full set of preclinical data to be presented at a conference in early 2021 Next Generation Gene Therapy Platform GLA Engineered for Stability Activi
Slide 18: Gene Therapy: Updates & Key Takeaways
18 Gene Therapy: Updates & Key Takeaways • CLN6 Phase 1/2 interim data show positive impact with potential to become first - ever approved gene therapy for fatal brain disease in children • Manufacturing on track to initiate next clinical studies in CLN6 and CLN3 in 2021 using material from planned
Slide 19: Financial Summary
“We are business led and science driven” - Amicus Belief Statement Financial Summary
Slide 20: 3Q20 Select Financial Results
20 3Q20 Select Financial Results Financial Summary Sept. 30, 2020 (in thousands, except per share data) Sept. 30, 2019 Product Revenue 67,437 48,768 Cost of Goods Sold 8,399 5,596 R&D Expense 70,419 58,892 SG&A Expense 37,850 39,680 Changes in Fair Value of Contingent Consideration 1,034 789 Depreci
Slide 21: Financial Outlook: Key Takeaways
21 Financial Outlook: Key Takeaways • Proceeds from July debt facility places Amicus firmly on a path to self - sustainability – Achieved through continued careful expense management, prioritization of early - stage research programs, and measured capital expenditures • Current cash position of $509
Slide 22: Closing Remarks
Closing Remarks “We are business led and science driven” - Amicus Belief Statement
Slide 23: Thank You
Thank You “Our passion for making a difference unites us” - Amicus Belief Statement
Slide 24: Appendix
Appendix
Slide 25: Reconciliation of Non-GAAP Financial Measures
Appendix Reconciliation Amicus Therapeutics, Inc. ‘Reconciliation of Non-GAAP Financial Measures (dn thousands) ‘Three Months Ended September 30, [Nine Months Ended September 30, 2020 2019 2020 2019 Total operating expenses ~as reported GAAP. S799 3 10087 3 308 3 26900 Research and development: ‘Sha